参附注射液辅助冠脉搭桥治疗冠心病疗效及对患者心脏收缩功能影响  

Effect of Shenfu injection on coronary systolic function in patients with coronary heart disease

作　　者：孙明霞[1] 杨书强[1] 高原 Sun Mingxia;Yang Shuqiang;Gao Yuan(Department of Thoracic Surgery,Anyang People＇s Hospital of Henan Province（Anyang 455000)

机构地区：[1]河南省安阳市人民医院心胸外科,安阳455000

出　　处：《陕西中医》2018年第7期869-872,共4页Shaanxi Journal of Traditional Chinese Medicine

基　　金：河南省科技厅科技攻关项目(113421423341)

摘　　要：目的:研究参附注射液辅助冠脉搭桥治疗冠心病的临床疗效对患者心脏收缩功能影响。方法:选取冠脉搭桥治疗冠心病患者108例,按照奇偶法,将纳入患者分为观察组和对照组(各54例),两组患者采用同样的冠脉搭桥术,观察组辅助以参附注射液、对照组予以等量葡萄糖注射液(或0.9%氯化钠注射液),7d为1个疗程,连续两个疗程。观察和比较两组患者术前、术后7d、术后14d心脏收缩功能、心肌损伤标志物、血脑钠肽(BNP)水平和术后随访60d心血管事件。结果:术后7d、术后14d,观察组患者左心室射血分数(LVEF)、右心室舒张期射血分数(RVEF)、心脏指数(CI)水平均高于对照组,左室舒张末期前后径(LVESD)、左室收缩末期前后径(LVESD)、左心室收缩压(LVSP)水平低于对照组,差异均有统计学意义(P<0.05)。血清肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)、BNP水平均低于对照组,差异均有统计学意义(P<0.05)。术后随访60d,观察组心血管事件率3.70%,低于对照组的18.52%,差异有统计学意义(P<0.05)。结论:参附注射液辅助冠脉搭桥术治疗冠心病能显著增强患者术后心脏收缩能力,降低术后并发症和死亡率,值得临床使用。Objective：To investigate the effect of Shenfu injection on coronary systolic function in patients with coronary heart disease.Methods：coronary artery bypass grafting was performed in 108 patients with coronary heart disease.According to the odd-even method,the patients were divided into observation group and control group（54 cases each）.The patients in the two groups received the same coronary artery bypass grafting.The patients in the observation group were given Shenfu injection,while the control group were given the same amount of glucose injection（or 0.9% sodium chloride injection）for 7 days for two courses.The systolic function,myocardial injury markers,BNP level and the cardiovascular events at 60 days after operation were observed before and 7 days after operation and 14 days after operation.Results：The levels of left ventricular ejection fraction（LVEF）,right ventricular ejection fraction（RVEF）and cardiac index（CI）in the observation group were significantly higher than those in the control group and the left ventricular end-diastolic dimension at 7 days and 14 days after operation LVESD,LVESD and LVSP were significantly lower than those of the control group（P〈0.05）.Serum levels of cTnI,CK-MB and BNP were significantly lower than those in the control group（P〈0.05）.After 60 days of follow-up,the incidence of cardiovascular events in the observation group was 3.70%,which was lower than that in the control group（18.52%）,the difference was statistically significant（P〈0.05）.Conclusion：Shenfu injection-assisted coronary artery bypass graft treatment of coronary heart disease can significantly enhance postoperative cardiac contractility and reduce postoperative complications and mortality,worthy of clinical promotion and use.

关 键 词：冠状动脉疾病/中西医结合疗法 参附注射液 @冠脉搭桥术 

分 类 号：R541.4[医药卫生—心血管疾病]